FACS

Hackensack University Medical Center and the John Theurer Cancer Center Ranked One of Newsweek's World's Best Specialized Hospitals

Retrieved on: 
Thursday, October 7, 2021
Magnet, Sarkis, Population health, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, NCI, Green guides, Patient, Hospital, Gold Seal Winery, Nursing, U.S. News & World Report Best Hospitals Rankings, Green Guide, Joseph M. Sanzari Children's Hospital, New York Red Bulls Academy, State, Physician, Great Hospital, Multimedia, Children's Cancer Institute, Academic health science centre, THE, Diagnosis, U.S. News & World Report, Cancer, TRUST, FACS, Hackensack Meridian Health, New, Joint Commission, Education, Cancer Institute, New Jersey-New York 7 Conference, Aftercare, COPD, Strathcona County, University Medical Center, Hackensack Meridian School of Medicine, Hospitality Review, News, CEO, Hackensack, Joseph, Heart failure, World, View, Research, Travel, Pharmaceutical industry, Medicine

HACKENSACK, N.J., Oct. 7, 2021 /PRNewswire/ -- Hackensack Meridian's Hackensack University Medical Center and its John Theurer Cancer Center has again ranked among the top hospitals in the Newsweek's 2022 World's Best Specialized Hospitals list.

Key Points: 
  • HACKENSACK, N.J., Oct. 7, 2021 /PRNewswire/ -- Hackensack Meridian's Hackensack University Medical Center and its John Theurer Cancer Center has again ranked among the top hospitals in the Newsweek's 2022 World's Best Specialized Hospitals list.
  • "I am immensely proud that John Theurer Cancer Center is recognized as one of World's Best Specialized Hospitalsby Newsweek," said Andre Goy, M.D., M.S., chairman and executive director of John Theurer Cancer Center.
  • John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's best cancer center, as recognized by U.S. News & World Report.
  • John Theurer Cancer Center is part of the Georgetown Lombardi Comprehensive Cancer Center, an NCI designated comprehensive cancer center.

CHRISTUS Health announces new affiliation with Texas A&M

Retrieved on: 
Thursday, October 7, 2021
Twitter, Texas A&M Health Science Center, Patient, Temple, Segal Design Institute, Bryan–College Station, ACGME, CHRISTUS Health, Texas A&M University System, Health, Accreditation, Accreditation Council, Physician, University college, Accreditation Council for Graduate Medical Education, Riverside University Health System Medical Center, Program, Endocrinology, Geriatrics, Marketing, Master of Education, Texas A&M Health Science Center College of Medicine, FACS, Education, Cardiology, University system, Tyler, MD, Â, Graduate medical education, University, Infection, DO, DIO, Senior, National Medical Commission, Texas A&M University, Communication, Partnership, Hospital, Student, Moses Austin, Research, Internal medicine, Internal, Medicine, Dentistry, Management

Texas A&M and CHRISTUS Health today announced a new collaboration to help ensure that Northeast Texas will have access to world-class health care for generations to come.

Key Points: 
  • Texas A&M and CHRISTUS Health today announced a new collaboration to help ensure that Northeast Texas will have access to world-class health care for generations to come.
  • Todays announcement is historic for our community, said Chris Glenney, FACHE, Senior Vice President Group Operations, CHRISTUS Health Northeast Texas.
  • In addition to the agreement with Texas A&M, the Accreditation Council for Graduate Medical Education (ACGME) has also approved transitioning the CHRISTUS Good Shepherd Internal Medicine Residency sponsorship from the University of Texas at Tyler to CHRISTUS Health.
  • This collaboration is the next step in a new beginning for the CHRISTUS program, said John C.McDonald, DO, FACOI; Chair, Academic Institute, CHRISTUS Health.

Sensorion Hosting Key Opinion Leader Webinar with Dr Nicole C. Schmitt on Cisplatin-Induced Ototoxicity on October 28, 2021

Retrieved on: 
Thursday, October 7, 2021
Biotechnology, Pharmaceutical, Health, Other Health, KOL, Neck, Emory University, Diagnosis, Hearing loss, GJB2, Fellowship of the Royal Colleges of Surgeons, University, Otorhinolaryngology, Therapy, American Head, Washington University School of Medicine, Deafness, Biomarker, American College, Head, FACS, Q&A, General surgery, Company, Epidemiology, Medical degree, Usher syndrome, American Academy of Otolaryngology–Head and Neck Surgery, Research, Incidence, Mutation, Dentistry

The webinar will feature a presentation by Key Opinion Leader Nicole C. Schmitt, MD, FACS (Emory University) who will provide an overview on hearing loss caused by cisplatin-induced ototoxicity, its epidemiology, the current treatment landscape, and the unmet medical need in adults.

Key Points: 
  • The webinar will feature a presentation by Key Opinion Leader Nicole C. Schmitt, MD, FACS (Emory University) who will provide an overview on hearing loss caused by cisplatin-induced ototoxicity, its epidemiology, the current treatment landscape, and the unmet medical need in adults.
  • Nicole C. Schmitt, MD, FACS, obtained her Medical Degree from Washington University School of Medicine in St. Louis, Missouri.
  • Dr. Schmitt is a head and neck surgical oncologist and scientist at Emory University in Atlanta, Georgia, USA.
  • Dr. Schmitt has been studying molecular mechanisms, incidence, and prevention strategies for cisplatin-induced ototoxicity since 2007.

ALASTIN Skincare® Announces Issuance Of Fifth And Sixth U.S. Patent Incorporating Revolutionary TriHex Technology®

Retrieved on: 
Wednesday, October 6, 2021
Technology, Elective surgery, Peptide, Patent, United States patent law, MHS, Multimedia, Adipose tissue, Restore, MD, Master of Medicine, United States Patent and Trademark Office, FACS, Marketing, Method, FCS, Science, Safety, Skin, Pharmaceutical industry, Medical device

U.S. Patent No.11,052,032 covers ALASTIN's platform TriHex Technology and US Patent No.

Key Points: 
  • U.S. Patent No.11,052,032 covers ALASTIN's platform TriHex Technology and US Patent No.
  • 11,103,455 relates to liposomal compositions, both associated with TransFORM Body Treatment.
  • These new patents are directed to methods for the use of topical compositions of TransFORM Body Treatment with TriHex Technology to improve skin laxity, texture or crepiness, with or without body contouring procedures or for targeting dermal white adipose tissue.
  • ALASTIN Skincare is dedicated to developing innovative, clinically-tested skin care products that correct, protect and maintain healthy skin for a lifetime.

Commonwealth Radiology Associates Announces New Partnership with Tufts Medical Center

Retrieved on: 
Wednesday, October 6, 2021
Medical Devices, Hospitals, Health, Radiology, Practice Management, Tufts University, Trauma, Partnership, Radiology, Health, Tufts Medical Center, Patient, CRA, Physician, Hospital, Faculty, FACS, Environment, CEO, Tufts University School of Medicine, TMC, Research, History, Lowell General Hospital, Medical Center, Medicine, Commonwealth Radiology Associates, Tufts Medical Center and Tufts Children’s Hospital, COMMONWEALTH RADIOLOGY ASSOCIATES, TUFTS MEDICAL CENTER AND TUFTS CHILDREN’S HOSPITAL

Today CRA announces a new partnership with world-renowned teaching hospital Tufts Medical Center (TMC) that will elevate quality, improve coverage, and enhance radiologist recruitment.

Key Points: 
  • Today CRA announces a new partnership with world-renowned teaching hospital Tufts Medical Center (TMC) that will elevate quality, improve coverage, and enhance radiologist recruitment.
  • The radiologists at Tufts Medical Center excel in tertiary/quaternary radiology working on the toughest cases in the area.
  • Commonwealth Radiology Associates (CRA) is the largest private practice radiology group in Massachusetts, providing imaging expertise in the northern suburbs of Boston.
  • Tufts Medical Center is an exceptional, not-for-profit, 415-bed academic medical center that is home to both a full-service hospital for adults and Tufts Childrens Hospital.

PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MBBS, Therapy, Clinical trial, Medical college, Pharmacokinetics, Medical College of Wisconsin, The Alfred Hospital, MIT, Pancreatic cancer, Royal Australasian College of Surgeons, Royal Australasian College, Pancreatic tumor, Cancer, Patient, Monash University, Physician, MD, Senior, Toxicity, FACS, Panther, University, Paclitaxel, Associate, Technology, Peter MacCallum Cancer Centre, Pancreas, Massachusetts Institute of Technology School of Engineering, Safety, Peter, Doctor of Philosophy, Medical imaging, Pharmaceutical industry, PTM-101, PanTher Therapeutics, PTM-101, PANTHER THERAPEUTICS

PanTher Therapeutics (PanTher), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, announced today the dosing of the first two patients in its Phase 1 first-in-human clinical trial of PTM-101 for the treatment of pancreatic cancer.

Key Points: 
  • PanTher Therapeutics (PanTher), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, announced today the dosing of the first two patients in its Phase 1 first-in-human clinical trial of PTM-101 for the treatment of pancreatic cancer.
  • Pancreatic cancer has one of the poorest prognoses of all malignancies, and responses to currently available systemic therapies are inadequate.
  • This first-in-human trial will evaluate feasibility, safety, and pharmacokinetics of PTM-101 when used as part of a standard procedure for treatment of patients with locally advanced pancreatic adenocarcinoma.
  • PanTher Therapeutics (PanTher) is a clinical-stage oncology company revolutionizing cancer care with a proprietary treatment platform designed to enhance therapeutic response while minimizing side effects.

Oral and maxillofacial surgeons honored for accomplishments in research, education, other areas

Retrieved on: 
Wednesday, October 6, 2021
American Association of Oral and Maxillofacial Surgeons, Survival, University, American Dental Association, Oral and maxillofacial surgery, Mouth, Safety, Risk, Proceedings of the Human Factors and Ergonomics Society Annual Meeting, Annual general meeting, Association, BCH, MS, Oral, BDS, Memory, National Institute of Dental and Craniofacial Research, JD, AAOMS, Health, Faculty, FACS, OMFS, Face, Arthrogram, National Institute, Foundation, Doctor of Philosophy, Journal of Oral and Maxillofacial Surgery, Awards and decorations of the Civil Air Patrol, Trustee, Education, American Association, MB, Golden Joystick Awards, Empire Special Honorary Awards, COVID-19, Exhibition, OMS, United, MBA, Research, Librarian of the Year Award, Dentistry

The awards presentation was held during the Opening Ceremony of the 103rd AAOMS Annual Meeting the largest gathering of oral and maxillofacial surgeons in the country in September.

Key Points: 
  • The awards presentation was held during the Opening Ceremony of the 103rd AAOMS Annual Meeting the largest gathering of oral and maxillofacial surgeons in the country in September.
  • Since 2020, the pandemic has significantly impacted the oral and maxillofacial surgery (OMS) specialty and AAOMS members' practices.
  • The experts in face, mouth and jaw surgery The American Association of Oral and Maxillofacial Surgeons (AAOMS) is the professional organization representing more than 11,000 oral and maxillofacial surgeons, OMS residents and OMS professional staff in the United States.
  • For additional information about oral and maxillofacial surgery, visit the AAOMS websites at AAOMS.org and MyOMS.org.

The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

Retrieved on: 
Tuesday, October 5, 2021
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Neoplasm, Bladder cancer, Probability, American Urological Association, Diagnosis, Radiology, Patient, Recurrence, Solution, Fatigue, CR, Risk, Intermediate, Private Securities Litigation Reform Act, Population, Disease, FACS, Twitter, Cancer, Hematuria, Principal, Company, Program, Growth, ATLAS, Journal, COVID-19, NYU Langone Health, Dysuria, Urinary bladder, Technology, View, TURBT, Urinary tract infection, Safety, Urologic disease, LG, Kaplan–Meier estimator, NMIBC, Nasdaq, SEC, The New England Journal of Medicine, Pharmaceutical industry, Medical imaging, the Phase 2b OPTIMA II Trial, UGN-102, UroGen Pharma Ltd., THE PHASE 2B OPTIMA II TRIAL, UGN-102, UROGEN PHARMA LTD.

The study was published online and will be in the January print edition of The Journal of Urology.

Key Points: 
  • The study was published online and will be in the January print edition of The Journal of Urology.
  • Approximately 50-60% of the 81,000 estimated new cases of non-muscle invasive bladder cancer (NMIBC) diagnosed in the U.S. in 2020 were low-grade.
  • Some patients require multiple TURBT surgeries per year, which may lead to post-operative and long-term morbidity for this patient population.
  • The OPTIMA II Phase 2b results showed a significant treatment response with sustained durability in non-surgical chemoablation of LG IR-NMIBC.

Newly Formed Lanier Biotherapeutics Enters into License Agreement with Alloy Therapeutics

Retrieved on: 
Tuesday, October 5, 2021
Therapy, ATX, Science and technology in Asia, White, Diabetic retinopathy, Senior, Psoriasis, Growth, Hives, Agreement, IND, Regeneron Pharmaceuticals, Cell, Gastritis, Rhinovirus, Biotechnology, LNR, Animal, Type 2, IL25, Polyp (medicine), Inflammation, CEO, MS, IL6, Leadership, Amgen, Retina, Asthma, Eli Lilly, Allergy, Genentech, FACS, Eosinophilic esophagitis, Company, Executive, Drug discovery, Doctor of Philosophy, GLOBE, 454 Life Sciences, Novartis, Cytokine, List of life sciences, Patient, Cancer, Central retinal vein occlusion, Atopic dermatitis, VEGF, MBA, Pharmaceutical industry, Management, Fine chemical, Vaccine

BOGART, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (Lanier or the Company), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2 Inflammatory specialty diseases, today announced that it has entered into a license agreement (the Agreement) with Alloy Therapeutics (Alloy), a privately held drug discovery company.

Key Points: 
  • BOGART, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (Lanier or the Company), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2 Inflammatory specialty diseases, today announced that it has entered into a license agreement (the Agreement) with Alloy Therapeutics (Alloy), a privately held drug discovery company.
  • Upon closing of the Agreement, Alloy will license to Lanier certain rights to AbeoMouseand Alloys ATX-Gxplatform of proprietary transgenic mouse strains.
  • Chairman, Kirby Alton, reprises his role of Chairman of Abeome, and brings deep product development expertise gained as one of Amgens original scientists.
  • Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together.

Allied OMS Partners With Facial & Oral Surgery Associates to Deliver Exceptional Care & Clinical Outcomes to More Patients in Texas

Retrieved on: 
Monday, October 4, 2021
Decision-making, Laser ablation, Partnership, Evidence-based medicine, Income, JPS Health Network, Patient, Health, Evidence-based dentistry, Physician, Alliance, 3D CT, FACS, CEO, Medicine, Rehabilitation, Private equity, Dentistry, 3D, OMS, Facial, Partner, Elective surgery, Oral cancer, Outsourcing, Doctor of Philosophy, Time, FOSA, Healthcare

"We're delighted to partner with the team at Facial & Oral Surgery Associates, who is known for delivering exceptional oral and maxillofacial surgical care to patients using the most advanced technologies in dentistry and medicine," said Dan Hosler, CEO of Allied OMS.

Key Points: 
  • "We're delighted to partner with the team at Facial & Oral Surgery Associates, who is known for delivering exceptional oral and maxillofacial surgical care to patients using the most advanced technologies in dentistry and medicine," said Dan Hosler, CEO of Allied OMS.
  • Facial & Oral Surgery Associates marks the sixth Texas practice in the Allied OMS family, expanding access to care to tens of thousands of patients throughout the state.
  • Headquartered in Southlake, Texas, Allied OMS has a total of nine partner practices serving patients out of 13 locations across Texas, Colorado, and California.
  • Facial and Oral Surgery Associates provides oral and maxillofacial surgical care in Fort Worth, Arlington, Weatherford, and surrounding areas.